Piper Jaffray analyst David Amsellem reiterated an Overweight rating and raised his price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE